Creo Medical Group PLC Director/PDMR Shareholding (0033N)
27 May 2022 - 4:01PM
UK Regulatory
TIDMCREO
RNS Number : 0033N
Creo Medical Group PLC
27 May 2022
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Director/PDMR Shareholding
Chief Financial Officer purchases 70,000 shares; Non-Executive
Chairman purchases 15,435 shares
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
it has received notification that Charles Spicer, Non-Executive
Chairman of Creo, and Richard Rees, Chief Financial Officer, have
purchased ordinary shares of GBP0.001 each in the Company
("Ordinary Shares").
Charles Spicer has purchased a total of 15,435 ordinary shares
at a price of 97.18p per ordinary share. Following this
transaction, Charles Spicer's total direct interest in the Company
held via his Self-Invested Personal Pension ("SIPP") is now 143,411
ordinary shares, representing approximately 0.08% of the Company's
issued share capital.
Richard Rees has purchased a total of 70,000 ordinary shares at
a price of 96.75p per ordinary share; 21,400 of these shares are
held via his SIPP. Richard Rees' total direct interest in the
Company is now 73,615 ordinary shares, representing 0.04% of the
Company's issued share capital.
Enquiries:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Numis Securities Limited (Joint
Broker)
Freddie Barnfield / James Black
/ Duncan Monteith +44 (0)20 7260 1000
Walbrook PR Ltd Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / +44 (0)7502
Phillip Marriage 558 258 / +44 (0)7867 984 082
About Creo Medical
Creo Medical is a medical device company focused on the
development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the
development and commercialisation of a suite of electrosurgical
medical devices, each enabled by CROMA, powered by Kamaptive. The
Group has developed the CROMA powered by Kamaptive full-spectrum
adaptive technology to optimise surgical capability and patient
outcomes. Kamaptive is a seamless, intuitive integration of
multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection,
coagulation and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled
surgical solutions. CROMA currently delivers bipolar radiofrequency
("RF") energy for precise localised cutting and focused high
frequency microwave ("MW") energy for controlled coagulation and
ablation via a single accessory port. This technology, combined
with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and
controlled clinical solutions. The Directors believe the Company's
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option for
procedures.
For more information, please refer to the website
www.creomedical.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Charles Spicer
--------------------------------------- ------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status Non-Executive Chairman
--------------------------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------
a) Name Creo Medical Group plc
--------------------------------------- ------------------------------------------
b) LEI 213800H188ZDCWWXFA21
--------------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.001 each
financial instrument,
type of instrument
Identification code GB00BZ1BLL44
b) Nature of the transaction Purchase of Ordinary Shares via SIPP
--------------------------------------- ------------------------------------------
c) Price(s) and volume(s)
------------------ -------------------
Price(s) Volume(s)
------------------ -------------------
97.18p 15,435
------------------ -------------------
d) Aggregated information
- Aggregated volume N/A - single transaction
- Price
e) Date of the transaction 26 May 2022
--------------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange
--------------------------------------- ------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Richard Rees
---------------------------- --------------------------------------
2 Reason for the notification
--------------------------------------------------------------------
a) Position/status Chief Financial Officer
---------------------------- --------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------
a) Name Creo Medical Group plc
---------------------------- --------------------------------------
b) LEI 213800H188ZDCWWXFA21
---------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.001 each
financial instrument,
type of instrument
Identification code GB00BZ1BLL44
b) Nature of the transaction Purchase of Ordinary Shares
Purchase of Ordinary Shares via SIPP
---------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
96.75p 48,600
----------
96.75p 21,400
----------
---------------------------- --------------------------------------
d) Aggregated information
- Aggregated volume 70,000
- Price GBP67,725.00
e) Date of the transaction 26 May 2022
---------------------------- --------------------------------------
f) Place of the transaction London Stock Exchange
---------------------------- --------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFEAESIRFIF
(END) Dow Jones Newswires
May 27, 2022 02:01 ET (06:01 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024